Key Takeaways
- The FDA's exclusion of GLP-1s from the 503B bulks list signals a narrowing of large-scale compounding, not an outright ban; 503A pharmacies can still compound these agents, but under increased scrutiny.
- Pharmacists should proactively address patient anxiety, demonstrate regulatory fluency, and help patients weigh legitimate alternatives like manufacturer assistance programs or direct-to-consumer access.
- Patients should be counseled to verify pharmacy licensure, question medication sourcing, and understand the difference between compounded and FDA-approved GLP-1 products.
In an interview with Pharmacy Times, Annie Lambert, PharmD, BCSCP, clinical program manager for compliance solutions at Wolters Kluwer, discussed the FDA's recent move to exclude glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly and Company), and liraglutide (Victoza, Saxenda; Novo Nordisk), from the 503B bulk compounding list and what this signals for pharmacists managing patients on compounded versions of these therapies.
Lambert framed the FDA's action as part of an ongoing, rapidly evolving regulatory environment rather than a sudden crackdown. By excluding GLP-1s from the 503B bulks and shortages list, she explained, regulators are reinforcing restrictions on bulk compounding pharmacies and signaling a broader narrowing of large-scale GLP-1 compounding. She noted that 503A pharmacies retain the ability to compound these agents but remain under heightened FDA scrutiny and that the agency has separately cautioned telehealth companies against marketing compounded GLP-1 products. According to Lambert, this shift represents a reaffirmation of compounding's intended role, addressing individual patient needs when FDA-approved medications are unavailable, rather than an outright restriction.
Turning to pharmacists' day-to-day practice, Lambert said many patients who began compounded GLP-1 therapy during recent shortages may feel anxious about how new regulations could affect their treatment. She encouraged pharmacists to demonstrate fluency in the regulatory landscape, maintain robust systems for quality, safety, and compliance, and help patients weigh alternatives such as manufacturer assistance programs or direct-to-consumer access when appropriate.
Lambert also outlined key messages pharmacists should share with patients using or considering compounded GLP-1s, including verifying the source of health information encountered through social media or advertising, consulting a clinician even if that provider is not prescribing the therapy, confirming a pharmacy's state licensure, and understanding the distinctions between compounded and FDA-approved products. Throughout, she emphasized that pharmacists remain one of the most trusted resources patients have for navigating safe, legitimate access to GLP-1 therapies.
